查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1133469

吉西他滨 HCL-2022-2029 的全球市场

Global Gemcitabine HCL Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 250 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场动态

Gemcitabine HCL 的市场增长受到多种因素的推动，例如老年人口的增加、癌症疾病的增加、技术进步以及改善治疗的研究工作。

癌症疾病的流行预计将推动市场增长

由于乳腺癌和胰腺癌的增加，全球对盐酸吉西他滨的需求正在增加。根据世界卫生组织 (WHO) 的数据，癌症是全球主要的死亡原因。 2020年的死亡人数约为1000万，据说六分之一的患者将死于癌症。最常见的癌症是乳腺癌、肺癌、结肠癌、直肠癌和前列腺癌。大约三分之一的癌症死亡是由高水平的肥胖、饮酒、吸烟、水果和蔬菜摄入量低以及缺乏运动引起的。根据世界卫生组织2022年2月的数据，据说到2020年，将有226万乳腺癌病例，221万肺癌病例，120万皮肤癌病例，193万大肠癌病例，我来了。此外，每年有 400,000 名儿童患上癌症。宫颈癌是最常见的癌症。癌症疾病的发病率随着年龄的增长而增加，主要是由于某些癌症危险因素随着年龄的增长而积累。为了治疗癌症患者，必须及时诊断癌症。如果早期发现并得到有效治疗，许多癌症可以治愈。治疗的正确选择涉及癌症和个体的考虑。盐酸吉西他滨静脉注射，属于一组称为抗代谢物的药物，与细胞中的正常物质非常相似。它是细胞週期特异性的。当细胞将这种物质纳入其新陈代谢时，它们就无法分裂。它主要通过在 DNA 合成过程中促进癌细胞的程序性细胞死亡来发挥其抗肿瘤作用。具体来说，它通过 G1/S 期边界抑制细胞进展。这可以防止细胞分裂并预防各种癌症。

盐酸吉西他滨的副作用阻碍市场增长

但是，盐酸吉西他滨的副作用包括异常虚弱、食慾不振、尿色深、手臂和肩部疼痛、突然剧烈头痛、发烧、发冷、身体疼痛、流感症状、听力问题、呼吸问题、研究表明胸痛和沈重。这些副作用给患者带来健康风险，并可能对市场增长产生不利影响。

COVID-19 影响分析

由于这些药物的抗病毒活性，COVID-19 的出现对全球对这些药物的需求产生了相当大的影响。为了防止这种新型病毒作为人类病原体传播，公共卫生专业人员必须诊断感染、遏制其传播并治疗其病因。例如，吉西他滨具有抗病毒活性，鑑于我们在治疗随后的病毒性疾病（如 MERS-CoV 和 SARS-CoV 感染）方面的经验，有一份可用于治疗 COVID-19 感染的药物清单。盐酸吉西他滨是一种这样的核甘类似物抑製剂。作为 SARS-CoV-2 治疗剂有效。因此，作为传染病的治疗剂，在市场上的需求量很大。随着全球感染冠状病毒的人数增加，全球需求也在增加。例如，根据世界卫生组织 2022 年 9 月的数据报告，全球有 609,848,852 例冠状病毒确诊病例。

另一方面，在大流行期间，交通限制和封锁使许多患者难以接受正常护理。但是，现在可以住院治疗，因为它在 2022 年中期而不是 2021 年逆转。预计该市场在预测期内也将显示出良好的增长。

全球盐酸吉西他滨市场报告将提供对大约 55 多个市场数据表、50 多个图表和 250 多页（大约）的访问。

内容

第一章市场研究方法和范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

  • 按应用划分的市场细分
  • 最终用户的市场细分
  • 按分销渠道划分的市场细分
  • 按地区划分的市场细分

第 4 章市场动态

  • 市场影响因素
    • 驱动程序
      • 老年人口增加
      • 癌症发病率增加
    • 限制
    • 盐酸吉西他滨的副作用
    • 影响分析

第五章行业分析

  • 波特五力分析
  • 供应链分析
  • 监管机构分析
  • 流行病学

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按应用程序

  • 胰腺癌
  • 非小细胞肺癌
  • 膀胱癌
  • 软组织肉瘤
  • 转移性乳腺癌
  • 卵巢癌

第 8 章最终用户

  • 医院
  • 居家护理
  • 专业设施
  • 其他

第 9 章分销渠道

  • 医院药房
  • 在线药店
  • 零售店

第 10 章按地区划分

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 11 章竞争格局

  • 主要发展和战略
  • 公司份额分析
  • 产品基准

第 12 章公司简介

  • 礼来公司
    • 公司概况
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • Teva Pharmaceutical Industries Ltd.
  • Accord-UK Ltd.
  • Pfizer, Inc.
  • Mylan N.V.
  • Sun Pharmaceutical Industries Ltd.
  • Fresenius Kabi AG
  • Dr. Reddy's Laboratories Ltd.
  • Ingenus Pharmaceuticals
  • NuCana Biomed's

第 13 章。Gemcitabine HCL 全球市场-DataM

简介目录
Product Code: DMPH5860

Market Overview

Gemcitabine HCL Market size was valued at US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of X% during the forecast period (2022-2029).

Gemcitabine HCL is an FDA-approved drug with antineoplastic activity. It can be taken as a stand-alone or with other drugs. It is used for breast cancer, non-small cell cancer, ovarian cancer, pancreatic cancer, and others. This medication is given to the patient by injection into a vein by healthcare professionals. The dosage is based on the patient's medical condition, body size, and response to treatment.

Market Dynamics

The gemcitabine HCL market growth is driven by several factors, such as an increase in the geriatric population, an increase in cancer diseases, technological advancements, and research activities for improvising the treatment.

The prevalence of cancer disease is expected to drive the market growth

The rise in breast cancer, pancreatic cancer, and many more is increasing the demand for gemcitabine HCL globally. According to the World Health Organization (WHO), cancer is the main cause of death globally. Approximately 10 million deaths in 2020 will be due to cancer, or nearly one in six deaths of patients. The most common cancers are breast, lung, colon, rectum, and prostate cancers. Around one-third of all cancer deaths are due to high body mass index, alcohol consumption, tobacco use, low vegetable, and fruit intake, and lack of physical activity. According to WHO data from February 2022, in 2020, there will be 2.26 million cases of breast cancer, 2.21 million cases of lung cancer, 1.20 million cases of skin cancer, and 1.93 million cases of colon and rectum cancer worldwide. In addition, every year, 400,000 children develop cancer. Cervical cancer is the most common cancer. The incidence of cancer disease increases with age, mostly due to risk factors building up for specific cancers that rise with age. To treat a cancer patient, it is necessary to diagnose cancer on time. Many cancers can be cured if detected early and treated effectively. In the proper selection of treatment, both cancer and the individual are considered for treatment. Gemcitabine HCL is given intravenously and belongs to a family of drugs called antimetabolites, which are very similar to normal substances within the cell. It is cell-cycle specific. When the cells incorporate these substances into the cellular metabolism, they are unable to divide. Mainly, it shows anitumor effects by promoting programmed cell death of cancer cells undergoing DNA synthesis. Specifically it blocks progression of cells through the G1/S-phase boundary. That's how it prevents the division of cells and prevents different cancers.

The side effects of gemcitabine HCL will hamper the growth of the market

However, studies have shown side effects of gemcitabine HCL, such as unusual weakness, loss of appetite, dark urine, pain spreading to the arm or shoulder, sudden severe headache fever, chills, body aches, flu symptoms, hearing problems, breathing problems, and chest pain and heavy feeling. These side effects create health risks among patients, which may adversely affect the market's growth.

COVID-19 Impact Analysis

The appearance of COVID-19 considerably impacted the global demand for these drugs due to their antiviral activity. In order to prevent the novel virus from rising into a pandemic human pathogen, it is essential that public health professionals can diagnose the infection, control its spread, and treat its causes. For instance, due to the antiviral activity of gemcitabine, HCL is compiled in the list of drugs with the potential to be used in the treatment of COVID-19 infection based on experience in treating a subsequence of viral diseases such as MERS-CoV and SARS-CoV infection. Gemcitabine hydrochloride is one of the nucleoside analog inhibitors for this purpose. It is valid for the treatment of SARS-CoV-2 treatment. Due to this, the demand is high in the market to treat the infection. As the cases of coronavirus rise worldwide, the demand has increased worldwide. For instance, as per the WHO data report of September 2022, the confirmed cases of coronaviruses are 609,848,852 globally.

On the other hand, many patients faced difficulty receiving their regular treatments during the pandemic due to transportation restrictions and lockdowns. However, because the situation is reversing in the middle of 2022 rather than 2021, the patient can now receive treatment in the hospital. The market will also show good growth in the forecast period.

Segment Analysis

The pancreas cancer segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The pancreatic cancer segment is expected to hold the dominant market share over the period forecast (2022-2029). Pancreatic cancer is one of the cancers with high mortality and has a common survival rate of 6-8%. In recent years, cancer has been proven to be one of the deadliest in the United States, with high morbidity, typically in elderly patients. Nowadays, there exists a large unmet need for drugs and drug delivery vehicles that can provide excellent therapeutic advantages. Substantial interest in Gemcitabine as a combination therapy is gathering among researchers. An increasing body of studies on its pharmacology has propelled the revenue potential of key players in this segment. Furthermore, pancreatic cancer accounts for 8% of male deaths and 8% of female deaths in the United States, according to the American Cancer Society. In the United States, new cancer cases occur in 3% of males and 3% of females. In addition, more than 90% of cases develop in the exocrine tissue of the pancreas, which helps enzymes digest food. The less common endocrine tumors, mainly referred to as pancreatic neuroendocrine tumours (NETs), develop in hormone-producing cells and have a younger median age at diagnosis and better prediction.

Geographical Analysis

North America region holds the largest market share of the global gemcitabine HCL market

North America dominates the market for gemcitabine HCL and is expected to show a similar trend over the forecast period owing to the increased geriatric population, advanced healthcare infrastructure, increased incidences of cancer diseases, and favorable government initiatives. As per the American Cancer Society, Inc., 2022 report, nearly 1.9 million new cases are anticipated to be diagnosed in the U.S. alone, and there are 609,360 cancer deaths in the United States due to cancer. As we increase in age, there is a risk of developing cancer. 80% of the population diagnosed with cancer in the US is 55 years of age or older, and 57% are 65 or older due to certain behaviors such as drinking alcohol, eating habits, smoking, and having excess body weight. In addition, in the United States, it is estimated that 40 out of 100 men and 39 out of 100 women will develop cancer during their life span. With the increased number of cancer cases, there is more demand for gemcitabine HCL in the market to treat different cancers in patients.

Competitive Landscape

The gemcitabine HCL market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market are Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Accord-UK Ltd., Pfizer, Inc., Mylan N.V., Sun Pharmaceutical Industries Ltd., Fresenius Kabi AG, Dr. Reddy's Laboratories Ltd., Ingenus Pharmaceuticals and NuCana Biomed's among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the gemcitabine HCL market globally.

For instance,

  • In September 2022, NuCana plc announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Acelarin (NUC-1031), derived from the nucleoside analogs gemcitabine and 5-fluorouracil, respectively, two widely used chemotherapy agents. It is currently evaluated in a Phase III study for the first-line treatment of patients with advanced biliary tract cancer.

Stryker Corporation

Overview:

Eli Lilly and Company is an American pharmaceutical company headquartered in Indiana, founded in 1876, with a presence in 18 countries. The company receives profit from the marketing of its products for various cancer types for which gemcitabine HCL has been approved.

Product Portfolio:

Gemcitabine HCL:

Gemcitabine HCL is an oncology product for various cancer types. It is FDA approved for the treatment of breast cancer, non-small cell lung cancer, ovarian cancer, pancreatic cancer, and bladder cancer. In addition, it has been studied for its cytotoxic effect in various types of tumour treatment, including esophageal cancer.

The global Gemcitabine HCL market report would provide access to approximately 55+ market data tables, 50+ figures, and in the range of 250 (approximate) pages.

Table of Contents

1. Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet By Application
  • 3.2. Market snippet By End User
  • 3.3. Market Snippet By Distribution Channel
  • 3.4. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increase in geriatric population
      • 4.1.1.2. Increase in cancer diseases
    • 4.1.2. Restraints:
    • 4.1.3. Side effects of Gemcitabine HCL
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis
  • 5.4. Epidemiology

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Application

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Segment
    • 7.1.2. Market Attractiveness Index, By Application Segment
  • 7.2. Pancreas Cancer*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Non-small Cell Lung Cancer
  • 7.4. Bladder Cancer
  • 7.5. Soft-Tissue Sarcoma
  • 7.6. Metastatic Breast Cancer
  • 7.7. Ovarian Cancer

8. By End User

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 8.1.2. Market Attractiveness Index, By End User
  • 8.2. Hospitals*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Homecare
  • 8.4. Specialty Centers
  • 8.5. Others

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel Segment
  • 9.2. Hospital Pharmacy*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Online Pharmacy
  • 9.4. Retail Pharmacy

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking

12. Company Profiles

  • 12.1. Eli Lilly and Company*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Teva Pharmaceutical Industries Ltd.
  • 12.3. Accord-UK Ltd.
  • 12.4. Pfizer, Inc.
  • 12.5. Mylan N.V.
  • 12.6. Sun Pharmaceutical Industries Ltd.
  • 12.7. Fresenius Kabi AG
  • 12.8. Dr. Reddy's Laboratories Ltd.
  • 12.9. Ingenus Pharmaceuticals
  • 12.10. NuCana Biomed's

LIST NOT EXHAUSTIVE

13. Global Gemcitabine HCL Market- DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us